1. Home
  2. News
  3. Amplia Therapeutics Ltd.
  4. First Patient Recruited to ACCENT Trial in Pancreatic Cancer
More Amplia Therapeutics Ltd. news
Amplia Therapeutics Ltd.ASX: ATX

First Patient Recruited to ACCENT Trial in Pancreatic Cancer

Aug 2, 2022 at 2:14 AM EDT · Issued by Amplia Therapeutics Ltd.

Filed with ASX · Aug 2, 2022 at 2:14 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/first-patient-recruited-to-accent-trial-in-pancreatic-cancer

Amplia Therapeutics Ltd. on 6ix

Story so far

  • Ethics Clearance Phase 2 Trial - Pancreatic Cancer PatientsApr 6, 2022
  • AMP945 Improves Survival in Human Pancreatic Cancer ModelFeb 17, 2022
  • Phase 2 Trial in First-Line Pancreatic Cancer PatientsSep 15, 2021

Earlier from Amplia Therapeutics

  • Quarterly Activities and Cashflow Reports - June 2022 QtrJul 28, 2022
  • AMP945 Shows Efficacy in Model of Lung FibrosisJun 1, 2022
  • Preliminary Final Report and Annual Report YE 31 March 2022May 29, 2022
  • Amplia Receives Second Ethics Clearance for Phase 2 TrialMay 12, 2022
  • AMP945 Pre-IND Meeting OutcomeMay 8, 2022

Later from Amplia Therapeutics

  • CEO & Managing Director Presentation to AGMAug 25, 2022
  • Amplia Receives $1.8m R&D Tax IncentiveAug 30, 2022
  • CEO ResignationSep 11, 2022
  • AMP886 Activity in Acute Myeloid LeukemiaOct 2, 2022
  • Quarterly Activities and Cashflow Reports - Sep 2022 QtrOct 27, 2022
All Amplia Therapeutics news releases↗

Follow Amplia Therapeutics into a list and get an email when it puts out news.

Follow Amplia Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer